In a restructuring the company projects will annually save $80 million, Emergent is shuttering its Baltimore drug substance manufacturing facility and Rockville, Md., drug product facility.
The drugmaker, which manufactures Narcan nasal spray, is also reducing its workforce by about 300 employees, eliminating about 85 empty positions and creating a chief science officer role.
The restructuring is expected to cost between $18 million and $21 million.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
